Related Experiment Video

Updated: May 15, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Unpicking the combination lock for mutant BRAF and RAS melanomas

Bissan Al-Lazikani1, Paul Workman

  • 1Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Bissan.Al-Lazikani@icr.ac.uk

Cancer Discovery
|January 16, 2013
PubMed

Insights

Large-scale drug screening identified effective combination therapies for melanoma resistant to BRAF inhibitors. These genotype-selective treatments show promise in preclinical models of BRAF and RAS mutations.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Melanoma treatment resistance to BRAF inhibitors like vemurafenib is a significant clinical challenge.
  • Mutant BRAF and RAS oncogenes drive melanoma progression and therapeutic resistance.

Purpose of the Study:

  • To identify novel, genotype-selective therapeutic combinations for BRAF/RAS-mutant melanoma.
  • To overcome resistance mechanisms to existing BRAF inhibitor therapies.

Main Methods:

  • Unbiased, large-scale combinatorial drug screening was employed.
  • Preclinical models of BRAF and RAS mutant melanoma were utilized.

Main Results:

  • Effective genotype-selective drug combinations were identified.
  • Promising therapeutic activity was observed in preclinical models resistant to vemurafenib.

Conclusions:

  • Combinatorial drug screening is a viable strategy for discovering treatments against resistant melanoma.
  • Targeted combination therapies offer a promising avenue for overcoming vemurafenib resistance in melanoma.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...